Friday, 16 October 2026European Markets

CORBION Stock Bearish Momentum With A 10% Fall So Far On Monday

Loading stream...

(VIANEWS) - Shares of CORBION (AEX-Index: CRBN.AS) dropped by a staggering 10.03% to €21.70 at 14:08 EST on Monday, after five sequential sessions in a row of losses. AEX-Index is dropping 0.13% to €755.65, after five sequential sessions in a row of losses. This seems, at the moment, a somewhat bearish trend exchanging session today.

CORBION's last close was €24.12, 36.12% below its 52-week high of €37.76.

About CORBION

Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients in the Netherlands, the United States, Latin America, Asia, rest of North America, and rest of Europe, the Middle East, and Africa. The company offers ingredient solutions made from renewable resources for the food, home and personal care, animal nutrition, pharmaceutical, medical device, and bioplastics markets It markets its products through a network of sales offices and distributors. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1919 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, CORBION has a trailing twelve months EPS of €1.49.

PE Ratio

CORBION has a trailing twelve months price to earnings ratio of 14.56. Meaning, the purchaser of the share is investing €14.56 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.26%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 38.8%, now sitting on 1.46B for the twelve trailing months.

More news about CORBION (CRBN.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com